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Mitochondrial potassium channels, such as ATP-regulated or large conductance Ca2+-activated and voltage gated channels were implicated in
cytoprotective phenomenon in different tissues. Basic effects of these channels activity include changes in mitochondrial matrix volume,
mitochondrial respiration and membrane potential, and generation of reactive oxygen species. In this paper, we describe the pharmacological
properties of mitochondrial potassium channels and their modulation by channel inhibitors and potassium channel openers. We also discuss
potential side effects of these substances.
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Mitochondria play a fundamental role in energy generation
within the cell. Apart from this canonical role, mitochondria are
involved in other complex processes such as apoptosis. Mitochon-
drialmembrane permeabilization induces the release of cytochrome
c, Smac/DIABLO, and AIF, starting various apoptosis pathways.
Recently, an essential position of potassium transport through mi-
tochondrial innermembranewas identified to trigger cytoprotection
[1–3]. This transport is strictly ion channel dependent, and accor-
dingly, resembles plasma membrane ion channels activity. Po-
tassium selective ion channels were found to be present in inner
mitochondrial membrane [4–6]. Potassium ions control mitochon-Abbreviations: ANT, mitochondrial adenine nucleotide translocase; BKCa
channel, large conductance Ca2+-activated potassium channel; BLM, black lipid
membrane technique; ChTx, charybdotoxin; IbTx, iberiotoxin; KATP channel,
ATP-regulated potassium channel; mitoBKCa channel, mitochondrial large
conductance calcium-activated potassium channel; mitoKATP channel, mito-
chondrial ATP-regulated potassium channel; mitoKv1.3 channel, mitochondrial
voltage gated potassium channel; NS1619, 1,3-dihydro-1-[2-hydroxy-5-(tri-
fluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazole-2-one; SMP, sub-
mitochondrial particles
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[7]. The basic pharmacological properties of mitochondrial
potassium channels such as ATP-regulated potassium (mitoKATP)
channel, large conductance Ca2+-activated potassium (mitoBKCa)
channel and voltage dependent potassium (mitoKv1.3) channel
were found to be similar to some of the potassium channels present
in the plasma membrane of various cell types [8].
Rational application of different pharmacological substances
(channel inhibitors or potassium channel openers) helps in ex-
plaining the functional role of mitochondrial potassium channels
within the cell. In this paper, we describe the properties of mito-
chondrial potassium channels, their modulation by channel in-
hibitors and activators (potassium channel openers). Finally, we
also discuss side effects of these substances and their potential
contribution to cytoprotective effects.
2. Mitochondrial ATP-regulated K+ channel
The mitoKATP channel was initially described in isolated liver
mitochondria [9]. Subsequently, it was also identified in heart [10],
brain [11,12], renal [13], skeletal muscle [14] and human T-lym-
phocyte mitochondria [15]. The activity of this channel is modu-
lated by various nucleotides [10] (see Fig. 1). Recently, it was
shown that ATP effects on the mitoKATP channel can be modulated
by Ca2+ [15].
Fig. 1. Physiological regulators of the mitochondrial potassium channels: ATP-
regulated potassium (mitoKATP) channel, large conductance Ca
2+-activated
potassium (mitoBKCa) channel and voltage dependent potassium (mitoKv1.3)
channel. ROS, reactive oxygen species; NO, nitric oxide.
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unknown. Immunological studies identify both pore forming Kir
6.1 and Kir6.2 subunits in brain mitochondria [16]. It has also been
hypothesized that a complex of five proteins (including succinate
dehydrogenase) in the mitochondrial inner membrane is capable of
transporting K+ with characteristics similar to those of the mito-
KATP channel [17]. Recently, adenine nucleotide translocase was
implicated in ATP-sensitive K+ transport into mitochondria [18–
20]. Interestingly, the involvement of adenine nucleotide translo-
case in K+ traffic was also suggested before description of the KATP
channel activity in inner mitochondrial membrane [20].
Similarly, molecular properties of the mitochondrial sulfonyl-
urea receptor (mitoSUR) are also not clear. The use of the sulfo-
nylurea derivative [125I]glibenclamide leads to labeling of a 28
kDa protein in heart mitochondria [21]. A 64 kDa protein was
labeled in brainmitochondriawith the use of the fluorescent probe
BODIPY-glibenclamide [11].
Activity of this channel is modulated by drugs known as potas-
sium channel openers [22]. All of the potassium channel openers
applied on mitochondria were previously used to regulate plasma
membrane ATP-regulated potassium channel or large conductance
calcium-activated potassium channel. Despite this, potassium
channel openers such as diazoxide and BMS191095, are consi-
dered mitoKATP-selective openers. Similarly, 5-hydroxydecanoicacid has some mitochondrial specificity as mitoKATP channel
blocker.
An important contribution to understanding the pharmacolog-
ical properties of the mitoKATP channel comes from the use of the
techniques allowing single channel recording i.e. patch clamp or
black lipid membranes [9,15,23–25]. The observed K+ channel
activity is in fact a mitoKATP channel if the following phar-
macological properties are present in the recorded potassium
channel:
(1) The channel has to be blocked by ATP/Mg [9,10,23,26],
(2) The ATP/Mg-inhibited channel should be activated by the
potassium channel opener diazoxide [26,27],
(3) The channel should be blocked by 5-hydroxydecanoic acid
(5-HD), a substance known to be a blocker of the mito-
chondrial channel [23,24,26],
(4) The channel should be blocked by glibenclamide [9,10,26],
(5) The plasma membrane cardiac KATP channel blocker
HMR1098 should be without effect on the channel activity
[23,28],
Some of the substances acting on mitoKATP show additional
effect on isolated mitochondria. Diazoxide is known to inhibit
mitochondrial succinate dehydrogenase [29] and induce uncou-
pling of mitochondria [30,31]. Similar effects were observed with
potassium channel opener—pinacidil [30]. Glibenclamide is also
able to uncouple mitochondria at a high concentration [32] or to
induce mitochondrial permeability transition [33]. Recently, it
was shown that 5-HD is rapidly converted to 5-HD-CoA by
mitochondrial fatty acyl-CoA synthetase and acts as a weak
substrate or inhibitor of respiration in the employed conditions
[34,35]. Hence, in some reports the existence of the mitoKATP
channel in inner mitochondrial membrane is questioned [19,35–
37]. It is proposed that the pharmacological preconditioning by
mitoKATP channel modulators may be related to partial inhibition
of respiratory chain complexes [35,38].
These side effects may contribute to the overall effects of
substances used in experimental models with active metabolism,
for example in experiments on isolated mitochondria or cells (see
Table 1). For example, application of 5-HD, as the KATP channel
blocker, may be questioned in experimental models with active
acyl-CoA synthase [35]. Additionally, the channel opener – dia-
zoxide – has a complex action on mitochondrial membrane po-
tential [39], ROS production [40] and mitochondrial permeability
transition pore [41].
3. Mitochondrial large conductance calcium-activated
potassium channel
A putative mitochondrial large conductance Ca2+-activated
potassium channel (mitoBKCa channel) was originally described
using patch-clamp technique in human glioma cells LN229 [42].
This channel, with a conductance of 295 pS, was stimulated by
Ca2+ and blocked by charybdotoxin. Later the presence of a
channel with properties similar to the surface membrane calcium-
activatedK+ channel (stimulated by the potassium channel opener
NS1619 and blocked by charybdotoxin, iberiotoxin and paxilline)
Table 1
Pharmacological regulators of mitochondrial potassium channels: mitochondrial ATP-regulated potassium (mitoKATP) channel, large conductance calcium-activated
potassium (mitoBKCa) channel and voltage gated potassium (mitoKv1.3) channel. BLM—black lipid membranes technique
Postulated
channel target
Compound
[inhibitor/activator]
Experimental
setup
Applied
concentration
or dose
Comments [References]
mitoKATP Glibenclamide
[inhibitor]
Patch-clamp/
BLM
10–100 μM Studies performed on liver [9] and heart mitochondria [23,25]
Proteoliposomes
flux
0.3–1 μM K+ flux with reconstituted partially purified channel [27]
Isolated
mitochondria
0.3–50 μM Studies performed on rat liver mitochondria [27]
and skeletal muscle mitochondria [14]
Tissue 50 μM [52]
5-hydroxydecanoic acid
[inhibitor]
Patch-clamp/
BLM
10 μM–1 mM [15,23,24,53]
Proteoliposomes
flux
200 μM [54]
Isolated
mitochondria
40 μ M–1 mM Studies performed on mitochondria isolated from heart [55,56],
skeletal muscle [14] liver [26], kidney [13] and brain [46]
Cells/tissue 10 μM–1 mM Studies performed on cardiomiocytes [57–59], vascular smooth
muscle cells [60], endothelial cells [61] and neuronal cultures [62].
quinine [inhibitor] BLM 3–100 μM Additionally 86Rb+ flux and [3H]glibenclamode binding
experiments were performed [53]
N-ethylmaleimide
[inhibitor]
BLM 2 mM Reconstitution of inner mitochondrial membrane from beef [23]
Diazoxide [activator] Proteoliposomes
flux
0.3–3 μM K+ flux with reconstituted partially purified channel [27]
Isolated
mitochondria
10–100 μM [14]
BLM 10–50 μM Reconstitution of inner mitochondrial membrane from beef [23], [53]
and rat heart mitochondria [24] were performed
Cells/tissue 3.5 mg/kg [63]
Cromakalim [activator] Proteoliposomes
flux
0.3–10 μM K+ flux with reconstituted partially purified channel,
two developmental cromakalim analogues EMD60480
and EMD57970 were also applied [27]
Pinacidil [activator] Isolated
mitochondria
50 μM [30]
BMS191095 [activator] Isolated
mitochondria
10–30 μM Studies performed on heart and brain mitochondria [46,64,73]
Cells 10–40 μM Studies were performed with primary rat cortical neuronal cultures [65]
Tissue 0.4–10 mg/kg [66–69]
6 μM [70,71],
RP66471 [activator] Isolated
mitochondria
100 μM Studies performed with liver mitochondria [72]
Nicorandil [activator] Tissue 1.75 mg/kg [63]
Isolated
mitochondria
10–100 μM Studies performed with rat skeletal muscle mitochondria [14]
P1075 [activator] Tissue 100 μM [52]
Proteoliposomes
flux
0.1–1 μM [52]
Isoflurane [activator] BLM 0.8 mM Reconstitution of inner membrane from rat heart mitochondria [24]
were performed
mitoBKCa Charybdotoxin (ChTx)
[inhibitor]
Patch-clamp 1–200 nM Mitoplasts from glioma cell line and cardiac tissue were used [42,43]
Mitochondrial
flux
100 nM The surface of cardiac myocytes was permeabilized
with the use of saponin. ChTx slowed K+ uptake
(measured with fluorescent probe PBFI) by approximately 20-fold [43]
Iberiotoxin (IbTx)
[inhibitor]
Mitochondrial
flux
100 nM The surface of cardiac myocytes was permeabilized
with the use of saponin [43]
Paxilline [inhibitor] 2 μM Paxilline was also used to block the protective effect
of NS1619 in the experiments of the ischemic damage
experiments [43]
NS1619 [activator] Mitochondrial
flux
30 μM [43]
(continued on next page)
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Table 1 (continued)
Postulated
channel target
Compound
[inhibitor/activator]
Experimental
setup
Applied
concentration
or dose
Comments [References]
mitoBKCa Cells 30 μM [44]
mitoKv1.3 Margatoxin (MgTx)
[inhibitor]
Patch-clamp 2 nM Studies were performed on T lymphocytes mitochondria [51]
Isolated
mitochondria
10 nM A relatively high concentration of toxin was used to
promote a rapid diffusion to the inner membrane and
to achieve complete inhibition [51]
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guinea pig ventricular cells [43]. Immunoblots of cardiac mito-
chondria with antibodies against the C terminal part of BKCa
channel identified a 55 kDa protein as putative channel which
may contribute to the cardioprotective effect of K+ influx into
mitochondria. Very recently, it was reported that cardiac mito
BKCa activation by NS1619 (measured by flavoproteins oxida-
tion) is amplified by 8-bromoadenosine-3′,5′-cyclic monophos-
phate and forskolin [44]. This suggests that opening of mitoBKCa
is modulated by cAMP-dependent protein kinase.
It should be mentioned that the mitoBKCa channel may offer a
novel link between cellular/mitochondrial calcium signaling and
mitochondrial membrane potential-dependent reactions. Altered
intramitochondrial calcium levels directly affect the potassium
permeability of the mitochondrial inner membrane thus modula-
ting the membrane potential. This type of interaction can mo-
dulate the efficiency of oxidative phosphorylation in a calcium-
dependent manner.
The pharmacological, biophysical and molecular character-
istics of this channel appear to be similar to the following pro-
perties of the well known plasma membrane large conductance
potassium channel (BKCa-channel, slo 1) [45]:
(i) The mitochondrial channel is potassium selective and ac-
tivated by calcium ions.
(ii) The channel is inhibited by iberiotoxin and charybdotoxin
at nanomolar concentrations.
(iii) The channel is activated by NS1619 at low micromolar
concentrations.
Very likely, the mitochondrial channel has its charybdotoxin/
iberiotoxin binding site close to the cytosolic compartment since
those compounds as peptides cannot easily enter the mitochon-
drial matrix space. Consequently, the calcium binding site of the
mitoBKCa channel is close to the matrix compartment (cf. orien-
tation of the plasma membrane BKCa channel [45]).
Similar to the mitochondrial ATP-regulated potassium chan-
nel, this novel potassium channel is expected to affect mito-
chondrial metabolism due to regulation of matrix volume [7]. In
addition to this classical physiological effect of mitochondrial
potassium transport, a pivotal role of mitochondrial potassium
channels has been implicated in cardio- and neuroprotection
[1,2,46]. It is therefore reasonable to expect a possible cyto-
protective effect of mitoBKCa channel activation, probably in the
presence of superoxide radicals [47]. Recently, it was shown that
cardioprotective effects of estradiol include the activation ofmitoBKCa channel in cardiac mitochondria [48]. Additionally, it
was suggested that the β1 subunit of BKCa channel is present in
inner mitochondrial membrane and interacts with cytochrome c
oxidase subunit I [48].
It has also been reported that twoBKCa channel openers,NS004
and NS1619, inhibit mitochondrial function in human glioma cells
due to inhibition of the complex I of mitochondrial respiratory
chain [49]. Recently, a channel opener NS1619 was shown to
inhibit the function of isolated cardiac mitochondria in similar
manner [50].
4. Voltage regulated potassium channel in innermitochondrial
membrane
Recently, a margatoxin-sensitive voltage gated Kv1.3 channel
was identified in T lymphocytesmitochondria [51] with the use of
patch-clamp, electron microscopy and immunological studies.
Interestingly, it was shown that Kv1.3 is present both in the plas-
ma andmitochondrial membranes, despite lacking the N-terminal
mitochondrial targeting sequence. Mitochondrial Kv1.3 channel
my represent an important factor in the apoptotic signal trans-
duction [51].
5. Final remarks
Until presently, three different potassium channels have been
reported to contribute to the potassium permeability of mito-
chondria—the ATP-regulated potassium channel (mitoKATP
channel), the large conductance Ca2+-activated potassium
channel (mitoBKCa channel) and the voltage gated Kv1.3 chan-
nel. Although the precise molecular identity of these channels
remains to be elucidated, their control of mitochondrial potassium
transport has two important implications:
Small alterations in the potassium permeability contribute to
physiological regulation of the mitochondrial matrix volume.
A larger increase in the potassium permeability of the mito-
chondrial inner membrane affects the mitochondrial membrane
potential (mild uncoupling) with potential beneficial effects on
cell survival under pathological conditions.
In this review, various classes of substances that interact with
mitochondrial potassium channels have been presented. They play
an important role in identification and characterization of mito-
chondrial channels in different tissues. In light of the ubiquitous
presence of mitochondrial identified potassium channels, novel
opportunities for novel drug development have been emerged.
To reach this stage, however, the molecular identification of
719A. Szewczyk et al. / Biochimica et Biophysica Acta 1757 (2006) 715–720mitochondrial potassium channels (especially mitoKATP channel)
requires significant progress. Moreover, drugs specific to the new
mitochondrial channels (lacking cross-reactivity with plasma
membrane channels or other enzymes present in mitochondria)
will have to be synthesized.
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